S troke outcomes are inversely related to tissue plasminogen activator (tPA) treatment time. 1 Physicians have little influence over time from stroke onset to patient arrival at the hospital. Thus, it is important to identify delays in time from hospital arrival to tPA administration, door-to-treatment time (DTT), to reduce overall tPA delivery time. Currently, <30% of patients have DTT less than the recommended 60 minutes. 2 One potential DTT delay may be prethrombolytic antihypertensive treatment (AHT). Previous work at a single academic stroke center showed that prethrombolytic AHT was not associated with delayed DTT, but patients who received more intense AHT had delayed DTT compared with those who received less intense AHT. 3 In this study, we sought to determine whether prethrombolytic AHT was associated with delayed DTT among acute stroke patients treated at community hospitals.
Materials and Methods
The Increasing Stroke Treatment through Interventional Behavior Change Tactics (INSTINCT) trial is a multicenter, cluster-randomized, controlled trial of the effectiveness of an educational intervention to increase appropriate tPA use at Michigan community hospitals without a dedicated acute stroke team. The treatment hospitals had assistance with development of an acute stroke protocol that was based on the University of Michigan Stroke Protocol, which was derived from the American Heart Association guidelines and the National Institute of Neurologic Diseases and Stroke tPA protocol. Hospitals in the control group used locally developed protocols or pathways. All tPA-treated cases at the 24 community hospitals were captured.
Primary Outcome and Covariates
All outcomes and covariates were abstracted by study nurses from the emergency department medical records. The primary outcome was DTT in minutes. The primary predictor was prethrombolytic Background and Purpose-Identifying modifiable tissue plasminogen activator treatment delays may improve stroke outcomes. We hypothesized that prethrombolytic antihypertensive treatment (AHT) may prolong door-to-treatment time (DTT). Methods-We performed an analysis of consecutive tissue plasminogen activator-treated patients at 24 randomly selected community hospitals in the Increasing Stroke Treatment through Interventional Behavior Change Tactics (INSTINCT) trial between 2007 and 2010. DTT among stroke patients who received prethrombolytic AHT were compared with those who did not receive prethrombolytic AHT. We then calculated a propensity score for the probability of receiving prethrombolytic AHT using logistic regression with demographics, stroke risk factors, home medications, stroke severity (National Institutes of Health Stroke Scale), onset-to-door time, admission glucose, pretreatment blood pressure, emergency medical service transport, and location at time of stroke as independent variables. A paired t test was performed to compare the DTT between the propensity-matched groups. Results-Of 534 tissue plasminogen activator-treated stroke patients analyzed, 95 received prethrombolytic AHT.
In the unmatched cohort, patients who received prethrombolytic AHT had a longer DTT (mean increase, 9 minutes; 95% confidence interval, 2-16 minutes) than patients who did not. After propensity matching, patients who received prethrombolytic AHT had a longer DTT (mean increase, 10.4 minutes; 95% confidence interval, 1.9-18.8) than patients who did not receive prethrombolytic AHT. AHT. Up to 5 prethrombolytic medication administrations were abstracted. Antihypertensive medications administered included Labetalol, Diltiazem, Nicardipine, Hydralazine, Clonidine, Metoprolol, Enalapril, Nitroprusside, Nitroglycerin, and Esmolol. Based on our previous work, gender, onset-to-door time, and stroke severity (National Institutes of Health Stroke Scale) were included. 4 Additionally, race, history of stroke, hypertension, diabetes, coronary artery disease, hypercholesterolemia, smoking status, antiplatelet or beta blocker as home medication, admission glucose, pretreatment blood pressure, emergency medical service usage, and location at time of stroke were included as we hypothesized an association with DTT.
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Statistical Analysis
Population characteristics were summarized using descriptive statistics. DTT among stroke patients who received and did not receive prethrombolytic AHT were compared using a t test. To account for differences between the AHT and non-AHT groups on potential predictors of DTT, we used propensity score matching, a method for bias reduction in observational studies. First, we calculated a propensity score for the probability of receiving prethrombolytic AHT using a logistic regression model including all variables associated with AHT. Individual patients with and without AHT were matched 1-to-1. A paired t test was then performed to compare the DTT between the propensity-matched groups. A separate generalized estimating equations approach was used to estimate the differences between patients receiving prethrombolytic AHT and those who did not while accounting for within-hospital clustering. Analyses were conducted with SAS 9.2. This project was approved by the Institutional Review Boards at the University of Michigan and the community hospital systems. Continuous variables are presented as means (standard deviations); categorical variables are presented as counts (proportions). AHT indicates antihypertensive treatment before thrombolysis; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; SDP, standardized difference proportion.
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Results
From 2007 to 2010, 557 consecutive patients among 25 578 (2.1%) stroke patients received intravenous tPA; DTT was missing for 23 patients, leaving 534 patients for analysis. Eighteen percent (95 patients) received prethrombolytic AHT. Labetalol (72%) was the most frequently administered antihypertensive medication. Patients who received prethrombolytic AHT were older, more likely to be African American, more likely to have a history of hypertension and diabetes, more likely to be using antiplatelet agents, had higher pretreatment glucose and blood pressures, and had shorter onset-to-door times than those who did not receive prethrombolytic AHT (Table) . In the unmatched cohort, patients who received prethrombolytic AHT had a longer DTT (89 minutes; standard deviation, 27) than those patients who did not (80 minutes; standard deviation, 31; mean increase, 9 minutes; 95% confidence interval, 2-16 minutes).
Of the 95 patients who received prethrombolytic AHT, propensity score-matched patients not receiving AHT were identified for 88 patients, resulting in 2 groups with excellent balance on individual covariates (Table) and nearly identical distributions of propensity scores. After matching, patients who received prethrombolytic AHT had a longer DTT (89 minutes; standard deviation, 26) than patients who did not receive prethrombolytic AHT (78 minutes; standard deviation, 28; mean increase, 10.4 minutes; 95% confidence interval, 2-18 minutes). This effect persisted and its magnitude was not altered by accounting for clustering within hospitals.
Discussion
In our study of >500 acute stroke patients treated with intravenous tPA at 24 community hospitals, we observed that prethrombolytic AHT was associated with a modest delay in DTT. The clinical significance of a 10-minute delay in DTT within a 60-minute window is unknown but theoretically important. 5 Notably, nearly 20% of patients had prethrombolytic hypertension, consistent with other studies. 3, 6 The American Heart Association/American Stroke Association recently launched "Target: Stroke," a quality-improvement initiative to reduce DTT. 7 Timely treatment of prethrombolytic hypertension, although common, is not one of the suggested best practices to decrease DTT.
Current prethrombolytic AHT guidelines are based on small observational studies. 8 Studies evaluating the association of prethrombolytic hypertension and intracranial hemorrhage and neurological outcomes are mixed. 6, 9, 10 Several limitations exist. Only presenting blood pressures were available, and thus we cannot determine if AHT was warranted in all patients. Data for doses of AHT and number of repeat AHT medication doses administered were not available. All patients were treated at community hospitals and may not be representative of patients treated in academic medical centers. As with most observational studies, we are unable to account for unmeasured confounders.
In summary, AHT before tPA administration was associated with delayed DTT and represents a target for future quality-improvement initiatives. Initiating AHT as soon as the patient is deemed an intravenous tPA candidate, careful monitoring of blood pressure after dosing AHT to determine if the patient will require additional AHT dosing, or study of the safety of administering intravenous tPA and then treating the elevated blood pressure are potential mechanisms to shorten the delayed DTT imposed by AHT. Further studies are needed to determine the optimal management of prethrombolytic hypertension.
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